Prelude Therapeutics, a Wilmington-based, clinical-stage pharmaceutical company, raised $60 million in a recently closed Series B funding round, the company announced.
The $60 million raised brings to $90 million the amount the company has raised to date, Prelude Therapeutics said in a press release.
Prelude Therapeutics develops small molecule drugs that target the growth of cancer cells.
The company received a $474,491 Delaware Strategic Fund grant in 2017.
Prelude’s founder and CEO, Dr. Kris Vaddi, was part of the founding team at Wilmington-based Incyte Corp.
Click here to read the Prelude Therapeutics press release.
The Delaware Division of Small Business wants to help you start or grow your business in Delaware.
Contact us to see how we can help you.
Related Topics: Council on Development Finance, Delaware Division of Small Business, Prelude Therapeutics
Delaware's Governor
State Agencies
Elected Officials
General Assembly
Delaware Courts
State Employees
Cities & Towns
Delaware State Code
State Regulations
Business First Steps
Phone Directory
Locations Directory
Public Meetings
Voting & Elections
Transparency
Delaware Marketplace
Tax Center
Personal Income Tax
Privacy Policy
Weather & Travel
Contact Us
Corporations
Franchise Tax
Gross Receipts Tax
Withholding Tax
Delaware Topics
Help Center
Mobile Apps
E-mail / Text Alerts
Social Media
Built by the Government Information Center
©MMXXIV Delaware.gov
